Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Alexandria Real Estate Equities-backed exosome therapy developer Codiak Biosciences has filed to raise up to $100m having pulled back from an earlier offering last year.

Alexandria Venture Investments contributed to a $91.5m round for Korro, which is working on RNA therapies for liver, eye and central nervous system diseases.

Optum Ventures returned to help the patient engagement platform developer close a round that came just two months after its last funding.

Debiopharm Innovation Fund and Crédit Mutuel Innovation co-led an $11.9m round for the digital pain management technology provider.

The drug discovery technology producer received $50m from strategic partner Bayer in the round, which valued it at about $1.2bn post-money.

Illumina's cancer diagnostics spinoff, which has raised more than $1.9bn in funding, has filed to float on the Nasdaq Global Select Market.

The Vietnam-focused venture firm’s maiden fund has attracted commitments from limited partners Naver, Sea and Woowa Brothers on the way to a $50m target.

The $14.6m round was co-led by distribution partner Fosun Pharma and also featured existing investor Baidu Ventures,

Grifols agreed the deal five years after supplying $50m in equity and development financing for the neurodegenerative disease therapy developer.